Successful oral desensitization to voriconazole in a patient with fungal arthritis caused by Exophiala sp.
case report
DOI:
https://doi.org/10.47456/rbps.v26i1.51201Keywords:
Voriconazole, Desensitization Immunologic, Exophiala, Infectious arthritisAbstract
Introduction: The impossibility of treatment due to allergy to antimicrobials is a major limitation in the treatment of infections. In these cases, desensitization becomes an alternative, especially when dealing with etiological agents with few treatment options available. Methods: Report of a successful case of desensitization to voriconazole, orally. Case report: We report the case of a 61-year-old man with systemic lupus erythematosus who developed fungal arthritis caused by exophiala sp., during treatment with voriconazole he developed erythematous skin lesions. With the discontinuation of voriconazole, the lesions improved, however, the change to itraconazole was not effective in treating the infection. Conclusion: Therefore, it was decided to carry out desensitization to voriconazole, which allowed a gradual increase in the dose of the antifungal with good tolerance to the treatment.
Downloads
References
Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8.
Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother. 2007 May;41(5):755-63.
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017 Feb;10(2):e004368.
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018 Apr;27(5):703-707.
Zwiener R, Marino G, Danna MM, Tamara B, Matias TB. Successful desensitization to voriconazole. J Allergy Clin Immunol 2013;131:AB166.
Jean T, Kwong K. Successful desensitization of voriconazole in na immunosuppressed pediatric patient. J Allergy Clin Immunol Pract. 2015 Jul-Aug;3(4):637-8.
Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Exophiala dermatitidis. World J Clin Cases 2021; 9(27): 7963- 72.
Narumoto O, Suzuki J, Takeda K, Tamura A, Nagai H, Matsui H. Rechallenge of voriconazole successfully tolerated after hepatic toxicity. Respir Med Case Rep. 2020 Aug 13;31:101191.
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018 Apr;27(5):703-707.
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017 Feb;10(2):e004368.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors and reviewers must disclose any financial, professional, or personal conflicts of interest that could influence the results or interpretations of the work. This information will be treated confidentially and disclosed only as necessary to ensure transparency and impartiality in the publication process.
Copyright
RBPS adheres to the CC-BY-NC 4.0 license, meaning authors retain copyright of their work submitted to the journal.
- Originality Declaration: Authors must declare that their submission is original, has not been previously published, and is not under review elsewhere.
- Publication Rights: Upon submission, authors grant RBPS the exclusive right of first publication, subject to peer review.
- Additional Agreements: Authors may enter into non-exclusive agreements for the distribution of the RBPS-published version (e.g., in institutional repositories or as book chapters), provided the original authorship and publication by RBPS are acknowledged.
Authors are encouraged to share their work online (e.g., institutional repositories or personal websites) after initial publication in RBPS, with appropriate citation of authorship and original publication.
Under the CC-BY-NC 4.0 license, readers have the rights to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material.
These rights cannot be revoked, provided the following terms are met:
- Attribution: Proper credit must be given, a link to the license provided, and any changes clearly indicated.
- Non-Commercial: The material cannot be used for commercial purposes.
- No Additional Restrictions: No legal or technological measures may be applied to restrict others from doing anything the license permits.
